China Pharmaceuticals Market 2022-2030

    Multi User License - $2,999

    In Stock

    Coming Soon

    CHINA PHARMACEUTICALS MARKET

     

    INTRODUCTION

    One of the most important sectors of the economy in the People’s Republic of China is the pharmaceutical sector, which includes manufactured medications and chemicals, ready-to-use Chinese medicines, medical equipment, tools, and supplies, as well as supplies for packaging and cleanliness.

    infographic: China Pharmaceuticals Market, China Pharmaceuticals Market Size, China Pharmaceuticals Market Trends, China Pharmaceuticals Market Forecast, China Pharmaceuticals Market Risks, China Pharmaceuticals Market Report, China Pharmaceuticals Market Share

     

    In terms of market size, China is home to the second-largest pharmaceutical industry. Despite having a sizeable portion of the world’s population, China only makes up a modest portion of the pharmaceuticals market.

     

     

    The evolving healthcare landscape in China aims to increase access to goods and services for people and to a broader percentage of the population by expanding basic health insurance.

     

    After the transitional era, it is anticipated that the pharmaceutical sector would keep growing.

     

    CHINA PHARMACEUTICALS MARKET SIZE AND FORECAST

     

    The China pharmaceuticals market accounted for $XX Billion in 2021 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2022 to 2030.

     

    MARKET DYNAMICS 

    One of the top pharmaceutical firms in China is Jiangsu Hengrui Medicine Co. Ltd., with its headquarters in Lianyungang, Jiangsu Province.

     

    Hengrui has always valued R&D and maintains an R&D office in Lianyungang. Both an R&D centre in Chengdu and Shanghai were constructed.

     

    Hengrui continues to make significant investments in R&D and has consistently ranked among the best companies in China in recent years.

     

    Hengrui is well renowned for its innovative anti-cancer medications and conducts research and development in oncology, metabolic disease, cardiovascular disease, inflammation, and diseases of the central nervous system and immune system, among other areas.

     

    The first small molecule anti-angiogenesis targeted therapy for advanced stomach cancer was apatinib, which the China FDA (CFDA) approved. The R&D departments of Hengrui have opened offices abroad in the US and Japan.

     

     

    Shijiazhuang Pharma Group: The pharma group is one of the biggest pharma enterprises in China and is based in Shijiazhuang, the capital city of Hebei Province in northeast China.

     

    The company declared the official release of its research medication butylphthalide. The consortium purchased the drug’s patents from the Chinese Academy of Medical Sciences and was used for clinical testing.

     

    Shijiazhuang Pharma Group is a classic example of a company developing new drugs. The company employs three strategies:

     

     

    first, collaborates with universities and research institutions to develop new drugs; second, applies for generic drug rights before the patents on patented drugs expire; and third, modernised traditional Chinese medicines (TCM), or develops TCMs in the same quantitative way as is done with Western medicines.

     

    COMPANY PROFILE

     

    THIS REPORT WILL ANSWER FOLLOWING QUESTIONS

    1. What is the average cost per China pharmaceuticals market right now and how will it change in the next 5-6 years?
    2. Average cost to set up a pharmaceuticals market in China?
    3. How many Chinas pharmaceuticals market is manufactured per annum globally? Who are the sub-component suppliers in different regions?
    4. What is happening in the overall public, globally?
    5. Cost breakup of a China pharmaceuticals market and key vendor selection criteria
    6. Where is the China pharmaceuticals market manufactured? What is the average margin per equipment?
    7. Market share of China pharmaceuticals market manufacturers and their upcoming products
    8. The most important planned China pharmaceuticals market in next 2 years
    9. Details on network of major China pharmaceuticals market and pricing plans
    10. Cost advantage for OEMs who manufacture China pharmaceuticals market in-house
    11. 5 key predictions for next 5 years in China pharmaceuticals market
    12. Average B-2-B China pharmaceuticals market price in all segments
    13. Latest trends in China pharmaceuticals market, by every market segment
    14. The market size (both volume and value) of China pharmaceuticals market in 2022-2030 and every year in between?
    15. Global production breakup of China pharmaceuticals market, by suppliers and their OEM relationship

     

     

     

    Sl no Topic
    1 Market Segmentation
    2 Scope of the report
    3 Abbreviations
    4 Research Methodology
    5 Executive Summary
    6 Introduction
    7 Insights from Industry stakeholders
    8 Cost breakdown of Product by sub-components and average profit margin
    9 Disruptive innovation in the Industry
    10 Technology trends in the Industry
    11 Consumer trends in the industry
    12 Recent Production Milestones
    13 Component Manufacturing in US, EU and China
    14 COVID-19 impact on overall market
    15 COVID-19 impact on Production of components
    16 COVID-19 impact on Point of sale
    17 Market Segmentation, Dynamics and Forecast by Geography, 2022-2030
    18 Market Segmentation, Dynamics and Forecast by Product Type, 2022-2030
    19 Market Segmentation, Dynamics and Forecast by Application, 2022-2030
    20 Market Segmentation, Dynamics and Forecast by End use, 2022-2030
    21 Product installation rate by OEM, 2022
    22 Incline/Decline in Average B-2-B selling price in past 5 years
    23 Competition from substitute products
    24 Gross margin and average profitability of suppliers
    25 New product development in past 12 months
    26 M&A in past 12 months
    27 Growth strategy of leading players
    28 Market share of vendors, 2022
    29 Company Profiles
    30 Unmet needs and opportunity for new suppliers
    31 Conclusion
    32 Appendix

     

    0
      0
      Your Cart
      Your cart is emptyReturn to Shop